Global Intravenous Iron Drugs 麻豆原创 Research Report 2023

Publication ID:

PB502233187

Publication Date:

February 6, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Iron is an essential element as it plays an important role in many vital biological processes such as the synthesis of heme which forms the basis of hemoglobin (Hb) the oxygen-carrying protein of the blood, the formation of myoglobin, energy metabolism, neurotransmitter production, the formation of collagen and immune system function. Lack of iron is one of the principal causes of anemia in the general population. It is not surprising that iron deficiency anemia (IDA) is associated with increased morbidity and mortality.
Highlights
The global Intravenous Iron Drugs market was valued at US$ 1449.2 million in 2022 and is anticipated to reach US$ 1977.2 million by 2029, witnessing a CAGR of 4.1% during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
Treatment with intravenous iron is clearly superior to oral iron and presents several advantages such as faster and higher increase in Hb levels and replenishment of body iron stores. For these reasons, modern formulations of IV iron have emerged as safe and effective alternatives for IDA management.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Intravenous Iron Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Intravenous Iron Drugs.
The Intravenous Iron Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Intravenous Iron Drugs market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Intravenous Iron Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Allergan
AMAG Pharmaceuticals
Daiichi Sankyo
Galenica
Pharmacosmos
Nippon Shinyaku
NOXXON Pharma
Rockwell Medical
Sanofi
Wanbang Biopharmaceutical
Segment by Type
Ferric Gluconate
Ferric Carboxymaltose
Iron Sucrose
Iron Dextran
Segment by Application
Nephrology
Gynecology & Obstetrics
Gastroenterology
Oncology
Cardiology
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Intravenous Iron Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Intravenous Iron Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Intravenous Iron Drugs 麻豆原创 Overview
1.1 Product Overview and Scope of Intravenous Iron Drugs
1.2 Intravenous Iron Drugs Segment by Type
1.2.1 Global Intravenous Iron Drugs 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 Ferric Gluconate
1.2.3 Ferric Carboxymaltose
1.2.4 Iron Sucrose
1.2.5 Iron Dextran
1.3 Intravenous Iron Drugs Segment by Application
1.3.1 Global Intravenous Iron Drugs 麻豆原创 Value by Application: (2023-2029)
1.3.2 Nephrology
1.3.3 Gynecology & Obstetrics
1.3.4 Gastroenterology
1.3.5 Oncology
1.3.6 Cardiology
1.3.7 Others
1.4 Global Intravenous Iron Drugs 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Intravenous Iron Drugs Revenue 2018-2029
1.4.2 Global Intravenous Iron Drugs Sales 2018-2029
1.4.3 Global Intravenous Iron Drugs 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Intravenous Iron Drugs 麻豆原创 Competition by Manufacturers
2.1 Global Intravenous Iron Drugs Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Intravenous Iron Drugs Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Intravenous Iron Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Intravenous Iron Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Intravenous Iron Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Intravenous Iron Drugs, Product Type & Application
2.7 Intravenous Iron Drugs 麻豆原创 Competitive Situation and Trends
2.7.1 Intravenous Iron Drugs 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Intravenous Iron Drugs Players 麻豆原创 Share by Revenue
2.7.3 Global Intravenous Iron Drugs 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Intravenous Iron Drugs Retrospective 麻豆原创 Scenario by Region
3.1 Global Intravenous Iron Drugs 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Intravenous Iron Drugs Global Intravenous Iron Drugs Sales by Region: 2018-2029
3.2.1 Global Intravenous Iron Drugs Sales by Region: 2018-2023
3.2.2 Global Intravenous Iron Drugs Sales by Region: 2024-2029
3.3 Global Intravenous Iron Drugs Global Intravenous Iron Drugs Revenue by Region: 2018-2029
3.3.1 Global Intravenous Iron Drugs Revenue by Region: 2018-2023
3.3.2 Global Intravenous Iron Drugs Revenue by Region: 2024-2029
3.4 North America Intravenous Iron Drugs 麻豆原创 Facts & Figures by Country
3.4.1 North America Intravenous Iron Drugs 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Intravenous Iron Drugs Sales by Country (2018-2029)
3.4.3 North America Intravenous Iron Drugs Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Intravenous Iron Drugs 麻豆原创 Facts & Figures by Country
3.5.1 Europe Intravenous Iron Drugs 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Intravenous Iron Drugs Sales by Country (2018-2029)
3.5.3 Europe Intravenous Iron Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Intravenous Iron Drugs 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Intravenous Iron Drugs 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Intravenous Iron Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Intravenous Iron Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Intravenous Iron Drugs 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Intravenous Iron Drugs 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Intravenous Iron Drugs Sales by Country (2018-2029)
3.7.3 Latin America Intravenous Iron Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Intravenous Iron Drugs 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Intravenous Iron Drugs 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Intravenous Iron Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Intravenous Iron Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Intravenous Iron Drugs Sales by Type (2018-2029)
4.1.1 Global Intravenous Iron Drugs Sales by Type (2018-2023)
4.1.2 Global Intravenous Iron Drugs Sales by Type (2024-2029)
4.1.3 Global Intravenous Iron Drugs Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Intravenous Iron Drugs Revenue by Type (2018-2029)
4.2.1 Global Intravenous Iron Drugs Revenue by Type (2018-2023)
4.2.2 Global Intravenous Iron Drugs Revenue by Type (2024-2029)
4.2.3 Global Intravenous Iron Drugs Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Intravenous Iron Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Intravenous Iron Drugs Sales by Application (2018-2029)
5.1.1 Global Intravenous Iron Drugs Sales by Application (2018-2023)
5.1.2 Global Intravenous Iron Drugs Sales by Application (2024-2029)
5.1.3 Global Intravenous Iron Drugs Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Intravenous Iron Drugs Revenue by Application (2018-2029)
5.2.1 Global Intravenous Iron Drugs Revenue by Application (2018-2023)
5.2.2 Global Intravenous Iron Drugs Revenue by Application (2024-2029)
5.2.3 Global Intravenous Iron Drugs Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Intravenous Iron Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Allergan
6.1.1 Allergan Corporation Information
6.1.2 Allergan Description and Business Overview
6.1.3 Allergan Intravenous Iron Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Allergan Intravenous Iron Drugs Product Portfolio
6.1.5 Allergan Recent Developments/Updates
6.2 AMAG Pharmaceuticals
6.2.1 AMAG Pharmaceuticals Corporation Information
6.2.2 AMAG Pharmaceuticals Description and Business Overview
6.2.3 AMAG Pharmaceuticals Intravenous Iron Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 AMAG Pharmaceuticals Intravenous Iron Drugs Product Portfolio
6.2.5 AMAG Pharmaceuticals Recent Developments/Updates
6.3 Daiichi Sankyo
6.3.1 Daiichi Sankyo Corporation Information
6.3.2 Daiichi Sankyo Description and Business Overview
6.3.3 Daiichi Sankyo Intravenous Iron Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Daiichi Sankyo Intravenous Iron Drugs Product Portfolio
6.3.5 Daiichi Sankyo Recent Developments/Updates
6.4 Galenica
6.4.1 Galenica Corporation Information
6.4.2 Galenica Description and Business Overview
6.4.3 Galenica Intravenous Iron Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Galenica Intravenous Iron Drugs Product Portfolio
6.4.5 Galenica Recent Developments/Updates
6.5 Pharmacosmos
6.5.1 Pharmacosmos Corporation Information
6.5.2 Pharmacosmos Description and Business Overview
6.5.3 Pharmacosmos Intravenous Iron Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Pharmacosmos Intravenous Iron Drugs Product Portfolio
6.5.5 Pharmacosmos Recent Developments/Updates
6.6 Nippon Shinyaku
6.6.1 Nippon Shinyaku Corporation Information
6.6.2 Nippon Shinyaku Description and Business Overview
6.6.3 Nippon Shinyaku Intravenous Iron Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Nippon Shinyaku Intravenous Iron Drugs Product Portfolio
6.6.5 Nippon Shinyaku Recent Developments/Updates
6.7 NOXXON Pharma
6.6.1 NOXXON Pharma Corporation Information
6.6.2 NOXXON Pharma Description and Business Overview
6.6.3 NOXXON Pharma Intravenous Iron Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 NOXXON Pharma Intravenous Iron Drugs Product Portfolio
6.7.5 NOXXON Pharma Recent Developments/Updates
6.8 Rockwell Medical
6.8.1 Rockwell Medical Corporation Information
6.8.2 Rockwell Medical Description and Business Overview
6.8.3 Rockwell Medical Intravenous Iron Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Rockwell Medical Intravenous Iron Drugs Product Portfolio
6.8.5 Rockwell Medical Recent Developments/Updates
6.9 Sanofi
6.9.1 Sanofi Corporation Information
6.9.2 Sanofi Description and Business Overview
6.9.3 Sanofi Intravenous Iron Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Sanofi Intravenous Iron Drugs Product Portfolio
6.9.5 Sanofi Recent Developments/Updates
6.10 Wanbang Biopharmaceutical
6.10.1 Wanbang Biopharmaceutical Corporation Information
6.10.2 Wanbang Biopharmaceutical Description and Business Overview
6.10.3 Wanbang Biopharmaceutical Intravenous Iron Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Wanbang Biopharmaceutical Intravenous Iron Drugs Product Portfolio
6.10.5 Wanbang Biopharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Intravenous Iron Drugs Industry Chain Analysis
7.2 Intravenous Iron Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Intravenous Iron Drugs Production Mode & Process
7.4 Intravenous Iron Drugs Sales and 麻豆原创ing
7.4.1 Intravenous Iron Drugs Sales Channels
7.4.2 Intravenous Iron Drugs Distributors
7.5 Intravenous Iron Drugs Customers
8 Intravenous Iron Drugs 麻豆原创 Dynamics
8.1 Intravenous Iron Drugs Industry Trends
8.2 Intravenous Iron Drugs 麻豆原创 Drivers
8.3 Intravenous Iron Drugs 麻豆原创 Challenges
8.4 Intravenous Iron Drugs 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Allergan
AMAG Pharmaceuticals
Daiichi Sankyo
Galenica
Pharmacosmos
Nippon Shinyaku
NOXXON Pharma
Rockwell Medical
Sanofi
Wanbang Biopharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.